DGIdb - ROCILETINIB Drug Record

ROCILETINIB chembl:CHEMBL3545308 Antineoplastic

Alternate Names:

CO-1686
ROCILETINIB
CS-1631
AVL-301
CNX-419

Drug Info:

Drug Class	Kinase Inhibitors

(1 More Sources)

Publications:

Nukaga et al., 2017, Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors., Cancer Res.
Walter et al., 2013, Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC., Cancer Discov
Sequist et al., 2015, Rociletinib in EGFR-mutated non-small-cell lung cancer., N. Engl. J. Med.

ROCILETINIB EGFR

Interaction Score: 2.58

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor

PMIDs:
28202511 24065731 25923550

Sources:
MyCancerGenome ChemblInteractions CIViC TTD

MyCancerGenome: CO-1686
- Version: 20-Jun-2017
Alternate Names:

CO-1686 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:

CIViC: ROCILETINIB

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Walter et al., 2013, Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC., Cancer Discov

Nukaga et al., 2017, Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors., Cancer Res.

Sequist et al., 2015, Rociletinib in EGFR-mutated non-small-cell lung cancer., N. Engl. J. Med.

TTD: CO-1686
- Version: 2020.06.01
Alternate Names:

D0M4AV TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL3545308
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL3545308
- Version: chembl_23
Alternate Names:

Drug Info:

Publications: